Compare OVBC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | PLX |
|---|---|---|
| Founded | 1872 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 182.9M |
| IPO Year | 1996 | 1996 |
| Metric | OVBC | PLX |
|---|---|---|
| Price | $44.18 | $2.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 18.8K | ★ 672.2K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ 1.53 | 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.90 | ★ $10.19 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.18 | $1.60 |
| 52 Week High | $51.25 | $3.19 |
| Indicator | OVBC | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 56.83 |
| Support Level | $44.33 | $2.59 |
| Resistance Level | $45.48 | $2.75 |
| Average True Range (ATR) | 1.24 | 0.09 |
| MACD | -0.30 | -0.00 |
| Stochastic Oscillator | 42.00 | 51.08 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services in Southeastern Ohio and western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers, and other standard banking products and services.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.